Somatrogon FDA Approval Status
Last updated by Judith Stewart, BPharm on Jan 12, 2021.
Somatrogon is an investigational, long-acting human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD).
Development Timeline for somatrogon
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.